泰它西普双靶点抑制BLyS/APRIL治疗狼疮性肾炎的真实世界数据
本研究基于倾向性评分匹配的真实世界数据,比较标准治疗联合泰它西普(80/160 mg每周一次)与仅标准治疗在成人狼疮性肾炎中的疗效与安全性。泰它西普组完全肾脏缓解率和主要疗效肾脏缓解率均显著高于对照组,蛋白尿下降更明显,V型狼疮性肾炎及蛋白尿>3 g/d患者获益更突出,安全性良好。
要点
- 泰它西普联合标准治疗可显著提高狼疮性肾炎完全肾脏缓解率和主要疗效肾脏缓解率。
- V型狼疮性肾炎及蛋白尿>3 g/d患者使用泰它西普的疗效更突出。
- 泰它西普组不良事件发生率与对照组相似,耐受性良好。
核心结论
- 联合泰它西普治疗的狼疮性肾炎患者疾病缓解更优,尤其在V型狼疮性肾炎和蛋白尿≥3 g/d患者中,且安全性良好。
研究设计与样本
- 真实世界研究,纳入接受泰它西普80/160 mg每周一次联合标准治疗的成人狼疮性肾炎患者,以仅接受标准治疗者为对照,采用1:1倾向性评分匹配。
主要发现
- 泰它西普组中位蛋白尿较基线下降0.97 g/d(63.82%),对照组下降0.31 g/d(25.31%)。
- 泰它西普组在SLEDAI-2K评分、医生总体评估评分及糖皮质激素剂量减少方面均显示显著治疗反应。
- 亚组分析显示泰它西普对V型狼疮性肾炎及蛋白尿>3 g/d患者疗效更突出。
临床怎么用
- 对于狼疮性肾炎患者,尤其是V型或蛋白尿>3 g/d者,可考虑在标准治疗基础上加用泰它西普80/160 mg每周一次以改善肾脏缓解。
- 治疗期间应监测蛋白尿变化及不良事件,泰它西普总体耐受性与标准治疗相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to evaluate the efficacy and safety of telitacicept for the treatment of lupus nephritis (LN) in real-world clinical practice. METHODS: Adult patients with LN receiving additional telitacicept at 80/160 mg once per week were recruited, while patients receiving only standard therapy were included as the control group using a 1:1 propensity score-matching approach. The primary outcomes were the proportions of patients achieving complete renal response (CRR) and primary efficacy renal response (PERR). RESULTS: Forty-four patients in both the control and telitacicept groups were enrolled, with median follow-up periods of 10.78 ± 3.37 and 10.5 ± 3.78 months, respectively. Compared with the control group, a significant improvement was observed in the proportion of patients achieving CRR (11.36% vs 29.55%, P = .034) and PERR (45.45% vs 68.18%, P = .031) in the telitacicept group at the last visit. Median proteinuria was reduced by 0.97 g/day (63.82%) from baseline in the telitacicept group, compared with a reduction of 0.31 g/day (25.31%) in the control group. Additionally, the telitacicept group showed notable treatment responses in the median SLE Disease Activity Index-2000 score, Physician's Global Assessment score and glucocorticoid dose reduction. Subgroup analysis revealed that telitacicept exhibited a more prominent therapeutic effect in patients with type V LN and those with proteinuria exceeding 3 g/day. Telitacicept was well tolerated, and the incidence of adverse events was similar between the two groups. CONCLUSIONS: LN patients receiving additional telitacicept treatment demonstrated better disease remission, particularly in those with type V LN and proteinuria ≥3 g/day, with a favorable safety profile in real-world clinical practice.
引用
- Jin J, Tan M, Tan Y, et al. Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis. Nephrol Dial Transplant. 2025. PMID: 40052354. doi:10.1093/ndt/gfaf049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。